Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease

被引：0
|
作者：
Yuksel, I. [1 ,2 ]
Baspinar, B. [1 ]
Durak, M. B. [1 ]
Kilic, V. [1 ]
Kivrakoglu, F. [1 ,2 ]
Guven, I. E. [1 ]
Kosar, K. [1 ]
Erdogan, C. [1 ]
Alkan, A. [3 ]
机构：
[1] Ankara City Hosp, Gastroenterol, Ankara, Turkey
[2] Ankara Yildirim Beyazit Univ, Gastroenterol, Sch Med, Ankara, Turkey
[3] Ankara Yildirim Beyazit Univ, Biostatist & Med Informat, Sch Med, Ankara, Turkey
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P536
引用
收藏
页码：I487 / I487
页数：1
相关论文
共 50 条
  • [1] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [2] Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Kadivar, Mohammad
    Molin, Daniel
    Angelison, Leif
    Hammarlund, Per
    Olin, Marie
    Torp, Jorgen
    Grip, Olof
    Nilson, Stefan
    Hertervig, Erik
    Lillienau, Jan
    Marsal, Jan
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [3] Infliximab biosimilar CT-P13 for inflammatory bowel disease
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 373 - 375
  • [4] Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Nakagawa, Tomoo
    Kobayashi, Taku
    Nishikawa, Kiyohiro
    Yamada, Fumika
    Asai, Satoshi
    Sameshima, Yulcinori
    Suzuki, Yasuo
    Watanabe, Mamoru
    Hibi, Toshifumi
    [J]. INTESTINAL RESEARCH, 2019, 17 (04) : 504 - 515
  • [5] CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease
    Albshesh, Ahmad
    Ben-Horin, Shomron
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 971 - 978
  • [6] A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
    Farkas, Klaudia
    Molnar, Tamas
    [J]. IMMUNOTHERAPY, 2018, 10 (02) : 107 - 117
  • [7] Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment
    Gompertz, M.
    Alfaro, I.
    Ricart, E.
    Lopez, A.
    Panes, J.
    Gallego, M.
    Barastegui, R.
    Giner, A.
    Vara, A.
    Masamunt, M.
    Ordas, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S427 - S428
  • [8] Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
    Jahnsen, Jorgen
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 322 - 329
  • [9] Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
    Mahmmod, Shaden
    Schultheiss, Johannes P. D.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    Gilissen, Lennard P. L.
    Hoentjen, Frank
    Lutgens, Maurice W. M. D.
    Mahmmod, Nofel
    Van der Meulen-de Jong, Andrea E.
    Smits, Lisa J. T.
    Tan, Adriaan C. I. T. L.
    Oldenburg, Bas
    Fidder, Herma H.
    [J]. INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 1954 - 1962
  • [10] Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease
    Kim, Eun Sil
    Choi, Sujin
    Choe, Byung-Ho
    Park, Sowon
    Lee, Yeoun Joo
    Sohn, Sang Jun
    Kim, Soon Chul
    Kang, Ki Soo
    Lee, Kunsong
    Shim, Jung Ok
    Kim, Yu Bin
    Hong, Suk Jin
    Lee, Yoo Min
    Kim, Hyun Jin
    Choi, So Yoon
    Kim, Ju Young
    Lee, Yoon
    Park, Ji-Sook
    Kim, Jae Young
    Yi, Dae Yong
    Lee, Ji Hyuk
    Choi, Kwang-Hae
    Jang, Hyo-Jeong
    Jeong, In Sook
    Kang, Ben
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 15
12345